Finecare CRP (hsCRP+CRP) Test Device
Finecare CRP (hsCRP+CRP) Rapid Quantitative Test Device for Infection & Sepsis Diagnosis
The Finecare CRP (hsCRP+CRP) Test Device (Finecare CRP (hsCRP+CRP) Rapid Quantitative Test Device) is a high-performance Point-of-Care Testing (POCT) solution that detects both high-sensitivity C-reactive protein (hsCRP) and standard CRP in human serum, plasma, or whole blood. Also known as Finecare CRP (hsCRP+CRP) Device /Finecare CRP (hsCRP+CRP) POCT Device. Compatible with the Finecare FIA Analyzer, it delivers quantitative, lab-accurate results in just 15 minutes, making it ideal for both acute infection diagnosis and chronic inflammation monitoring.
This dual-function test is widely used in hospitals, emergency departments, and clinics for diagnosing bacterial infections, sepsis, cardiovascular risk assessment, and inflammatory conditions such as rheumatoid arthritis. It supports early clinical decisions, enhances workflow, and improves patient outcomes.

Key Features:
- Dual-function: measures hsCRP and CRP
- Results in 15 minutes with Finecare FIA Analyzer
- Suitable for infection detection and cardiovascular risk evaluation
- Compact cassette format for easy point-of-care testing
- High accuracy, sensitivity, and ease of use
- Applicable in emergency care, primary care, and clinical laboratories
Packaging Information:
- Test Device: Single-use cartridge
- Storage Condition: 2°C – 30°C
- Shelf Life: Refer to the individual pack expiry date
- Lot Number: Available on packaging
- Instruction Manual Included


Nationwide Delivery Info:
- Finecare Device is Available Across Bangladesh
- Dhaka Metro: Same-day dispatch for orders placed before 2:00 PM
- Delivery to all major cities and districts
- Cash on Delivery (COD) available in selected areas
- Secure and fast courier partners are used

Customer Support
Need help? Contact our expert support team for installation help or clinical use guidance.
Phone: +8801405100400
Email: contact@medistorebd.com













Reviews
There are no reviews yet.